

- B1
Amended
18. The method of claim 17, which further comprises:
(d) conducting said x-ray crystallography on said modified RTK polypeptide.
19. The method of claim 17 wherein said truncated kinase insert domain comprises a deletion of the highly charged residues from the KID.
20. The method of claim 17 wherein said truncated kinase insert domain comprises a deletion of 50 residues from the KID.
21. The method of claim 17 wherein said truncated kinase insert domain comprises a deletion of 60 residues from the KID.
22. The method of claim 17 wherein said truncated kinase domain linking said helix D to said α helix E is of a sufficient length so as to allow said helices to maintain conformation associated with kinase structure.
23. The method of claim 17 wherein said RTK polypeptide is a member of the PDGFR family.
24. The method of claim 23 wherein said PDGFR member is selected from the group consisting of VEGFR-1, VEGFR-2, PDGFR- α , PDGFR- β , stem cell growth factor receptor (c-kit), and colony stimulating factor-1 receptor (CSF-1R/c-fms).
25. The method of claim 17 wherein said RTK polypeptide is selected from the group consisting of insulin receptor (IRK), fibroblast growth factor receptor-1 (FGFR-1), and VEGFR-2.
26. The method of claim 17 wherein said RTK polypeptide is VEGFR-2.
27. The method of claim 17 wherein said modified RTK polypeptide comprises the VEGFR2 Δ 50 polypeptide of SEQ ID NO: 5.
-